Amplius积极资产配置主动型ETF AAAA 深 沪
交易中 08-24 10:40:13 美东时间
30.545
-0.157
-0.51%
华盛通- 最 高30.59
- 今 开30.57
- 成交量 9750股
- 最 低 30.53
- 昨 收 30.702
- 总市值 2.83亿
- 52周最高 31.06
- 市盈率 静 --
- 换手率 0.11%
- 52周最低 25.1605
- 委 比 -4.76%
- 总股本 928.00万
- 历史最高 31.06
- 量 比 15.69
- 振 幅 0.20%
- 历史最低 24.4805
- 每 手 1
- 风险率 1.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多“国联绿色科技”递表港交所，国家级资质认证加持，蒸发冷技术构建核心壁垒
国联绿色科技于2026年5月11日向港交所递交招股书，拟在香港主板上市，联席保荐人为申万宏源香港、国联证券国际。公司是中国领先的全周期智慧能源管理解决方案提供商，2024年收入7.37亿元，净利润0.49亿元，毛利率19.27%；2025年收入6.39亿元，净利润0.5亿元，毛利率22.5%。据弗若斯特沙利文数据，按2025年收入计，公司位列中国第二大全周期智慧能源管理解决方案提供商，且是华东地区最大的全周期智慧能源管理服务商。公司自主研发了一系列高效蒸发冷产品及智慧能碳管理平台，并入选工信部信赖创新解决方案名单。主要股东包括国联发展集团、Johnson Controls、无锡地铁集团等。中介团队共计8家，保荐人2家，整体表现中规中矩。
05-14 17:11
DBV Technologies GAAP EPS of -$0.11
DBV Technologies press release (DBVT): Q1 GAAP EPS of -$0.11. Cash Position and LiquidityOn March 31, 2026, the Company held $229 million in Cash and Cash Equivalents compared to $194 million of Cash ...
05-01 05:09
DBV Technologies GAAP EPS of -$1.05
DBV Technologies press release (DBVT): FY GAAP EPS of -$1.05. On December 31, 2025, DBV held $194.2 million in cash and cash equivalents compared to $32.5 million of cash and cash equivalents on Decem...
03-27 17:16
Upstream Bio Plans To Initiate Dosing In Phase 3 Trials In Both Severe Asthma And CRSwNP In Q1 2027
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP –– Company plans to initiate
03-26 19:19
Ionis Unveils New Phase 3 Data For DAWNZERA In Rare Swelling Disorder
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses
02-27 20:06
The European Commission approves GSK's Exdensur (depemokimab) For Severe Asthma With Type 2 Inflammation And Chronic Rhinosinusitis With Nasal Polyps
GSK plc (LSE/NYSE:GSK) today announced the European Commission has approved Exdensur (depemokimab) in two indications:as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood
02-17 18:20
